Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

4 November 2024

Topic(s): Normative Guidance/Policies

Product(s): Cabotegravir, Dapivirine Vaginal Ring

Region(s): Sub-Saharan Africa

Countries: Eswatini

Type: Document

Download

Featured Resources

External Link

Integrated Study Dashboard

This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including lenacapavir for PrEP, cabotegravir, and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on…
External Link

Country Planning for Product Introduction Matrix

AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products, including lenacapavir (LEN), cabotegravir (CAB), and the Dapivirine Vaginal Ring (DVR), by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
Document

Ukraine HIV Clinical Guidelines 2025

These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
External Link

BLUPrInt PrEP Program Builder

The BLUPrInt PrEP Program Builder breaks down the process of making PrEP – whether oral or injectable – available in your setting into six manageable and coherent program components. Each program component includes a Step-by-Step Guide that presents key decision points and health equity considerations that are crucial to PrEP program development, a templated Standard…
Document

Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda, 2022

These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
Document

Malawi Service Delivery Guidelines and Standard Operating Procedures for the Provision of HIV Pre-Exposure Prophylaxis using Oral or Long-acting Injectable Options (2024)

The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.
External Link

Preferences for Long-acting Injectable HIV Pre-exposure Prophylaxis Service Delivery among Male and Female Sex Workers in Uganda: A discrete choice experiment

This article from PLOS Global Public Health explores service delivery preferences for injectable cabotegravir among heterosexual male sex workers and female sex workers in Uganda.
External Link

Dynamic Choice HIV Prevention with Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in East, Central, Southern, and West Africa: A cost-effectiveness modelling analysis

In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved prevention coverage; incident HIV infections were eliminated when long-acting cabotegravir was included as an option. This article from The Lancet HIV aims to assess…
External Link

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

This article from AIDS and Behavior explores preferences for various long-acting PrEP modalities amongst pregnant and lactating people in Botswana and South Africa. It further examines participants’ HIV risk perception during pregnancy and breastfeeding, their perceived individual-level facilitators and barriers of each PrEP modality, and the support needed by participants for PrEP uptake and continuation.
External Link

Global Forecast of Long-Acting PrEP Need for Key Populations (2025–2030)

Developed by AVAC, Avenir, and Global Black Gay Men Connect, this first-of-its-kind PrEP needs forecast estimates: 11.16 million person-years of PrEP needed annually by 2030 among men who have sex with men, transgender women, female sex workers, and people who inject drugs Uptake scenarios for cabotegravir, lenacapavir, and oral monthly PrEP Forecasts segmented by region,…